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Background: A class of analgesic α-conotoxins 
potently inhibits N-type calcium channels. 
Results: The activity of α-conotoxins Vc1.1 and 
RgIA was reduced following knockdown of 
GABAB receptor expression in sensory neurons 
and can be reconstituted in HEK 293 cells 
expressing human GABAB receptor and Cav2.2. 
Conclusion: GABAB receptors are needed for 
inhibition of Cav2.2 by Vc1.1 and RgIA. 
Significance: These analgesic α-conotoxins 
activate human GABAB receptors.  
 
SUMMARY 
α-Conotoxins Vc1.1 and RgIA are small 
peptides isolated from the venom of marine 
cone snails. They have effective anti-
nociceptive actions in rat models of 
neuropathic pain. Pharmacological studies in 
rodent dorsal root ganglion (DRG) show their 
analgesic effect is mediated by inhibition of N-
type (Cav2.2) calcium channels via a pathway 
involving γ-aminobutyric acid type B 
(GABAB) receptor. However, there is no 
direct demonstration that functional GABAB 
receptors are needed for inhibition of Cav2.2 
channel by analgesic α-conotoxins. This study 
examined the effect of the GABAB agonist 
baclofen and α-conotoxins Vc1.1 and RgIA on 
calcium channel currents following transient 
knockdown of the GABAB receptor using 
RNA interference. Isolated rat DRG neurons 
were transfected with siRNAs targeting both 
GABAB subunits. Efficient knockdown of 
GABAB receptor expression at the mRNA and 
protein level was confirmed by quantitative 
real time RT-PCR and immunocytochemical 
analysis, respectively. Whole-cell patch clamp 
recordings conducted 2–4 days after 
transfection showed that inhibition of N-type 
calcium channels in response to baclofen, 
Vc1.1 and RgIA was significantly reduced in 
GABAB receptor knockdown DRG neurons. 
In contrast, neurons transfected with a 
scrambled, non-targeting siRNA were 
indistinguishable from untransfected neurons. 
In the HEK 293 heterologous expression 
system, functional expression of both subunits 
of the human GABAB receptor was needed for 
the inhibition of Cav2.2 channels by Vc1.1 and 
RgIA. Together, these results confirm that 
GABAB receptors must be activated for the 
modulation of N-type (Cav2.2) calcium 
channels by analgesic α-conotoxins Vc1.1 and 
RgIA.  
Neuropathic pain is caused by damage or 
disease to the central or peripheral nervous 
system. It is a major health burden and poorly 
managed due to a lack of efficacious analgesics 
(1-3). Current pharmacotherapies, including 
opioids, anti-epileptics and antidepressants, have 
low efficacy and significant side effects (4,5). 
Therefore, there is a clinical need to develop 
novel drug leads to better treat neuropathic pain.  
Conotoxins (toxins isolated from the venom 
of marine cone snails) target a wide variety of 
membrane receptors and ion channels, and are a 
rich source of potential therapeutic agents. α-
Conotoxins are small peptides that typically 
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range in size from 12–19 amino acids, contain 
two disulfide bonds and usually have an 
amidated C-terminus. α-Conotoxin Vc1.1, a 
synthetic derivative of a peptide derived from 
the venom of the marine cone snail Conus 
victoriae, potently suppresses signs of pain when 
injected intramuscularly near the site of injury in 
rat models (6-8), demonstrating its potential as 
an analgesic therapeutic. RgIA, an α-conotoxin 
from Conus regius, has also been shown to 
significantly reduce chronic constriction nerve 
injury-induced hyperalgesia in rats (9,10).  
How α-conotoxins Vc1.1 and RgIA relieve 
neuropathic pain remains controversial. Both are 
highly potent antagonists of α9α10 nicotinic 
acetylcholine receptors (nAChR)4 (9-11), and 
Vc1.1 antagonizes the nicotine-induced increase 
in axonal excitability of unmyelinated C-fibers 
(12). Therefore, α9α10 nAChRs were proposed 
as the target for Vc1.1 and RgIA to mediate 
analgesia in chronic and neuropathic pain 
models (10). However, several structural analogs 
of Vc1.1 retain activity at α9α10 nAChRs, but 
lose their anti-allodynic effect (13,14). This 
suggests that a target other than α9α10 nAChR 
may contribute to the pain-relieving activity of 
α-conotoxins. Recent studies show that the 
analgesic α-conotoxins Vc1.1 and RgIA potently 
inhibit N-type calcium channel currents in rat 
sensory neurons (8,15,16). Pharmacological 
studies further reveal that Vc1.1 doesn’t interact 
directly with voltage-gated calcium channels 
(VGCC), but via a voltage-independent, G 
protein-coupled GABAB receptor-mediated 
mechanism (8,15). Collectively, these findings 
indicate that several different membrane 
receptors, including the GABAB receptor, may 
contribute to the pain-relieving activity of a class 
of α-conotoxins.  
To date, there is a lack of molecular studies 
confirming the interaction between α-conotoxins 
and GABAB receptor subunits, and 
demonstrating the need for functional GABAB 
receptor dimers for Cav2.2 channel inhibition by 
α-conotoxins. The present study examines 
whether or not a functional GABAB receptor is 
needed to link analgesic α-conotoxins and N-
type VGCC current inhibition.  
We took two different approaches to this 
study. First, we investigated VGCC currents in 
isolated rat dorsal root ganglion (DRG) neurons 
following transient knockdown of the GABAB 
receptor subunit expression using small 
interfering RNA (siRNA). Second, we 
investigated Cav2.2 channel modulation by 
Vc1.1 in HEK 293 cells stably expressing Cav2.2 
channels and transient transfection with both 
subunits of the human GABAB receptor. These 
approaches showed that GABAB receptor 
expression is necessary for the observed 
inhibition of N-type VGCCs by the α-conotoxins 
Vc1.1 and RgIA. A preliminary report of some 
of these results has been presented in abstract 
form.5  
 
EXPERIMENTAL PROCEDURES 
DRG neuron preparation – DRG neurons 
were enzymatically dissociated from ganglia of 
4- to 14-day-old Wistar rats according to 
standard protocols. Briefly, rats were killed by 
cervical dislocation, as approved by the RMIT 
University Animal Ethics committee, and the 
spinal cord removed. Ganglia of all areas of the 
spinal cord were collected in ice cold Hank’s 
Balanced Salt Solution (Invitrogen). They were 
incubated in 1 mg/mL collagenase (Sigma) in 
Hank’s Balanced Salt Solution for 30 min at 
37ºC, transferred to warm Neurobasal media 
(Invitrogen), and then triturated using a fire-
polished Pasteur pipette to obtain a cell 
suspension. The suspension was centrifuged at 
400 g for 5 min and immediately used for 
transfection.  
siRNA knockdown of GABAB receptor – 
Mission siRNA oligos (Sigma) for the rat 
gabbr1 gene (cat. no. SASI_Rn01_00121458) 
and gabbr2 gene (cat. no. 
SASI_Rn01_00107052), respectively, were used 
for transfection. Mission siRNA oligos 
comprising a scramble sequence with no 
homology to any known genes (siRNA 
Universal Negative Control #1) were used as a 
negative control. Mock transfected cells (without 
siRNA) served as an additional negative control. 
The siRNAs (100 nM final concentration of each 
siRNA duplex) were transfected into 
approximately 5 x 104 dissociated DRG cells 
using the Amaxa Nucleofector II electroporation 
system in combination with the Basic Neuron 
SCN Nucleofector Kit (both Lonza, Cologne, 
Germany) following the manufacturer’s 
protocol.  To identify transfected cells during 
electrophysiological experiments, 200 nM 
fluorescein-labeled oligonucleotide (Block-iT 
Fluorescent Oligo, Sigma) was added to the 
transfection reaction mixture. After transfection, 
the cells were suspended again in Neurobasal 
media containing B27 supplement (both 
Invitrogen), 0.5 mM L-glutamine and 1% 
penicillin/streptomycin and then seeded onto 
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poly-D-lysine-coated multiwell plates or glass 
cover slips. The cells were incubated under 
humidified conditions in 95% air and 5% CO2 at 
37ºC, and used after 1–4 days. 
Quantitative real time RT-PCR – RNA was 
isolated 24–48 h after transfection using the 
Absolutely RNA Nanoprep Kit (Agilent 
Technologies, Santa Clara, CA) and cDNA was 
synthesized from the RNA using the SuperScript 
III First-Strand Synthesis SuperMix (Invitrogen) 
for quantitative real time RT-PCR (qRT-PCR). 
Expression levels of GABAB R1 and GABAB R2 
mRNA were analyzed by qRT-PCR (Rotor-
Gene, Corbett Research, Sydney, Australia) 
using the SensiMix SYBR No-ROX Kit 
(Bioline, London, UK) and the following 
primers: 5’-TCA AGA TCA TTC TCA TGC 
CTG-3’ and 5’-GTG AAC TGG AGC CAT 
ATG AG-3’ for GABAB R1; and 5’-GAA CGA 
GAC CAA CTT CTT CG-3’ and 5-CTC TGC 
TGT CTT GAA ATT GAG-3’ for GABAB R2. 
Additionally, in each sample, the cDNAs of the 
housekeeping genes succinate dehydrogenase 
complex, subunit A, ubiquitin C and ribosomal 
protein L13a were amplified using standard 
primer sets (Mouse Normalisation Gene Panel, 
Bioline) to serve as internal references. Data 
were analyzed based on the comparative 
quantitation method (Rotor-Gene software, 
Corbett). For each sample, the relative 
expression level of GABAB receptor mRNA was 
calculated by comparing it with the geometric 
mean of the three housekeeping genes’ relative 
mRNA levels. 
Antibodies – The primary antibodies used 
were mouse monoclonal anti-βIII-tubulin 
(Promega, 1:2000), rabbit polyclonal anti-
GABAB R1 (Abcam, Cambridge, UK, cat. no. 
ab75239, 1:800) and rabbit monoclonal anti-
GABAB R2 (Abcam, cat. no. ab75838, 1:400) 
antibodies. The corresponding fluorescent 
secondary antibodies used were Alexa Fluor 
488-conjugated goat polyclonal anti-rabbit IgG 
antibody (Invitrogen, 1:1000) and Alexa Fluor 
555-conjugated goat polyclonal anti-mouse IgG 
antibody (Invitrogen, 1:1000). 
Double-labeling immunocytochemistry and 
confocal microscopy – Immunocytochemistry 
was performed on transfected DRG neurons 2–4 
days after transfection. DRG neurons were fixed 
in 4% paraformaldehyde for 15 min at room 
temperature. After two washes with PBS, the 
cells were pre-incubated in blocking solution 
(10% goat serum, 1% Triton X-100 in PBS) for 
30 min at room temperature, followed by 
overnight incubation at 4ºC with anti-β-III-
tubulin and either polyclonal anti-GABAB1 or 
monoclonal anti-GABAB2 antibodies in fresh 
blocking solution. After 2 washes with PBS, the 
fluorophore-conjugated secondary antibodies 
were applied for 1.5 h at room temperature. Cell 
nuclei were counterstained with DAPI. After 4 
more washing steps with PBS, the cells were 
sealed with fluorescence mounting media (Dako, 
Glostrup, Denmark). Control experiments 
determining the specificity of the 
immunocytochemical procedures were validated 
by omitting the primary antibodies. Images were 
acquired using a Nikon A1 laser-scanning 
confocal microscope equipped with a Plan Apo 
VC 60x water-immersion objective, an Argon 
laser (488 nm), a solid state laser (561 nm) and 
NIS Elements software using the same settings 
for siRNA-transfected and control cells. 
Quantitative analysis of GABAB receptor 
protein levels – DRG cells, immunolabeled as 
described above, were subjected to quantitative 
analysis of GABAB R1 receptor protein levels 
using a high-content imaging system 
(ImageXpress Micro, Molecular Devices, 
Sunnyvale, CA). Cells transfected with the 
siRNAs targeting the GABAB R1 and R2 
subunits were compared with cells transfected 
with the non-targeting negative control siRNA. 
For each siRNA treatment group, 756 sites (each 
containing an average of 3.3 neurons) were 
scanned. Neurons were identified by βIII-tubulin 
expression. A threshold for R1 fluorescence was 
set at above background or nonspecific staining 
levels. All βIII-tubulin-positive cells with above-
threshold fluorescence were counted as high R1-
expressing neurons. A difference in the 
percentage of high R1-expressing neurons 
between control and knockdown of GABABR1 
and GABABR2 (R1+R2 KD) cell batches would 
indicate successful knockdown. Moreover, to 
detect subtle differences in expression between 
high R1-expressing neurons of the control and 
R1+R2 KD cell batches, we further evaluated 
R1-fluorescence intensities indicating protein 
expression levels by dividing the sum of the 
grayscale intensity of R1 fluorescence by the 
total βIII-tubulin stained area.  
DRG and HEK 293 cell electrophysiology – 
DRG neurons were transfected with either 
GABAB receptor-specific siRNAs or negative-
control siRNA, and grown on poly-D-lysine-
coated glass cover slips for 1–4 days. Only DRG 
neurons exhibiting green fluorescence, due to 
co-transfection of the fluorescein-labeled 
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oligonucleotide, were selected for 
electrophysiological recordings. Cells were 
transferred into a small-volume (∼300 μL) 
recording chamber, constantly perfused with a 
solution containing (in mM) 
tetraethylammonium (TEA)-Cl 140, BaCl2 2, D-
glucose 10 and 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 10, pH 
7.4 (with NaOH). The internal pipette solution 
contained (in mM) CsCl 140, MgCl2 1, MgATP 
5, Na-GTP 0.1, bis(2-aminophenoxy)ethane-
N,N,N’,N’-tetra-acetic acid (BAPTA)-Cs4 5 and 
HEPES 10, pH 7.3 (with CsOH). Whole-cell 
Ba2+ currents were elicited from a holding 
potential of –80 mV, by 0.05-Hz, 200-ms step 
depolarizations to +10 mV. In each experiment, 
R1+R2 KD neurons and control neurons from 
the same batch of DRG preparation and 
transfection were tested successively. They were 
included for analysis only if the VGCC inward 
current inhibition in the R1+R2 KD neuron by 
baclofen was at least 10% less than the current 
inhibition by baclofen in the control neuron, 
indicating successful knockdown of the GABAB 
receptor. 
HEK 293 cells stably expressing human 
Cav2.2 channels (α1B, α2δ1 and β3 subunits) 
were transiently co-transfected with cDNAs 
encoding human GABAB R1 (10 μg), human 
GABAB R2 (10 μg) (OriGene Technologies, 
Inc., Rockville, MD) and enhanced green 
fluorescent protein (1 μg) (a reporter gene 
construct), using calcium phosphate precipitation 
(17). They were then cultured at 37◦C. In some 
experiments, cDNAs encoding the human 
dopamine receptor 2 (DRD2; OriGene 
Technologies) were used instead of GABAB R1 
and R2. Patch-clamp experiments were carried 
out 4–6 days after transfection, using the whole-
cell recording configuration. HEK 293 cells 
were superfused with a solution containing (in 
mM) BaCl2 10, CsCl 85, TEA-Cl 40, MgCl2 1, 
D-glucose 10 and HEPES 10, with pH 7.4 (with 
TEA-OH). Fire-polished borosilicate patch 
pipettes (2–3 MΩ tip resistance) were filled with 
a solution containing (in mM) Cs-
methenesulphonate 108, EGTA 9, MgCl2 4, 
MgATP 2, Na2GTP 0.5 and HEPES 9, pH 7.2 
(with CsOH). Typically, cells were voltage-
clamped at −80 mV and membrane currents were 
elicited by 0.1-Hz, 150-ms step depolarizations 
to −10 mV. 
Recordings were carried out using a 
Multiclamp 700B amplifier (Molecular 
Devices), controlled by a Clampex9.2/ 
DigiData1332 acquisition system at room 
temperature (23–25°C). Membrane currents 
were filtered at 2 kHz and sampled at 5 or 8 kHz. 
Leak and capacitative currents were subtracted 
using a −P/4 pulse protocol. Data were stored 
digitally on a computer for further analysis. Peak 
current amplitude in response to the depolarizing 
pulse was measured once a steady state was 
achieved (~ 5–10 min). Current densities were 
calculated by dividing the normalized current 
amplitude by the cell capacitance measured 
immediately before the recording. Current 
amplitudes obtained in the presence of the drug 
were normalized by dividing by the current 
amplitude obtained under control conditions. 
Chemicals and drugs – α-Conotoxins Vc1.1, 
RgIA and AuIB were synthesized as described 
previously (18-21) and provided as a stock 
concentration in H2O of ~ 1 mM by Dr RJ Clark 
(University of Queensland). The ω-conotoxins 
CVID and MVIIA were prepared as described 
previously (22). Baclofen and [D-Ala2, N-Me-
Phe4, Gly5-ol]-enkephalin acetate salt (DAMGO) 
were purchased from Sigma Aldrich. (2S)-3-
[[(1S)-1-(3,4-Dichlorophenyl)ethyl]amino-2-
hydroxypropyl](phenylmethyl) phosphinic acid 
hydrochloride (CGP55845) was purchased from 
Tocris Bioscience (Bristol, UK). All drugs were 
diluted to the appropriate final concentration and 
applied via perfusion in the bath solution. 
Baclofen was usually tested following the 
application of the α-conotoxin.  
Statistical analysis – Numerical data are 
presented as mean ± standard error of the mean. 
The statistical significance between two groups 
was evaluated by Student’s unpaired t-test. The 
statistical significance between three or more 
groups was evaluated by one-way ANOVA 
followed by Bonferroni’s post-hoc test. Values 
of P < 0.05 were considered to be statistically 
significant. All statistical analyses were achieved 
using Prism Version 5.1 (GraphPad Software 
Inc., La Jolla, CA). 
 
RESULTS 
Knockdown of GABAB receptor mRNA 
expression in DRG neurons – To effectively 
knockdown the expression of functional GABAB 
receptors (which are heterodimers of the two 
GABAB subunits R1 and R2), we tested siRNAs 
targeting either the R1 or the R2 subunit in 
isolated DRG neurons. qRT-PCR showed that 
following 24–48 h post-transfection, the mRNA 
levels of R1 in cells transfected with a R1-
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specific siRNA significantly decreased to 32.6 ± 
3.5% (n = 4) of control cells transfected with a 
scrambled, non-targeting siRNA (P < 0.0001) 
(Fig. 1A). R2 mRNA levels 24–48 h after 
transfection with the R2-specific siRNA were 
significantly reduced to 53.9 ± 8.0% (n = 4) of 
control (P = 0.0073) (Fig. 1B). A further 
increase in siRNA concentration (300 nM) didn’t 
lead to a further knockdown of either GABAB 
receptor subunit (data not shown). The 
scrambled, non-targeting siRNA-transfected 
control cells exhibited R1 and R2 expression 
levels almost identical to mock transfected (H2O 
transfected) cells (Fig. 1A, B). This indicated 
that there was not a nonspecific effect due to the 
siRNA transfection process itself.  
No off-target effects of the GABAB subunit-
targeting siRNAs were observed, because 
expression of the housekeeping genes, analyzed 
in parallel, was unaffected by the addition of 
siRNAs. Furthermore, when mRNA expression 
of a single GABAB receptor subunit was 
disrupted by siRNA, the expression level of the 
other subunit was not affected (Fig. 1A, B), 
indicating target-specific knockdown. Co-
transfection of the R1- and R2-targeting siRNAs 
(R1+R2 KD) demonstrated that knockdown of 
each subunit was equally effective compared 
with single-subunit knockdowns without 
interference (33.6 ± 6.1%, n = 5; P < 0.0001 
mRNA levels of R1, and 53.4 ± 13.3%, n = 5; P 
= 0.0265 mRNA levels of R2, respectively) (Fig. 
1A, B). Given that hetero-dimerization of R1 
and R2 subunits is essential for functional 
GABAB receptors (23), we used the co-
transfection protocol in the following 
experiments, expecting more effective 
knockdown. 
GABAB receptor protein knockdown by 
siRNA treatment – Immunofluorescence labeling 
of GABAB receptors in rat DRG neurons and 
visual inspection by confocal microscopy 
revealed an apparent decrease in fluorescence 
intensities for GABAB R1 and GABAB R2 in 
R1+R2 KD neurons compared with scrambled, 
non-targeting siRNA-transfected DRG neurons 
(Fig. 2A, B). The difference in intensity of R1 
immunostaining was quantified using a high-
content imaging system. In these experiments, 
we focused on R1 immunofluorescence because 
R2 immunofluorescence intensity and specificity 
were not as high as that of R1. The analysis 
revealed that the percentage of cells with R1-
specific immunofluorescence above the set 
threshold was significantly lower in the R1+R2 
KD group (35.1 ± 3.6%, n = 6) compared with 
control cells (57.3 ± 1.2%, n = 6; P = 0.0002) 
(Fig. 3B). Furthermore, the fluorescence 
intensities of R1, which indicate expression 
levels, in cells with above-threshold R1 
fluorescence were 20.2 ± 5.4% lower in 
knockdown cells compared with control cells (n 
= 6; P = 0.0206) (Fig. 3C). Taken together, the 
above data demonstrated that GABAB receptor 
knockdown by siRNA effectively decreases 
GABAB receptor protein expression in DRG 
neurons. 
Impairment of α-conotoxin-mediated 
inhibition of VGCC currents by GABAB receptor 
knockdown – R1+R2 KD DRG neurons were 
used in patch-clamp experiments to characterize 
the activity of the GABAB receptor agonist 
baclofen and α-conotoxins Vc1.1 and RgIA. 
Control and R1+R2 KD neurons exhibited 
comparable VGCC currents upon depolarization 
to +10 mV from a holding potential of –80 mV 
(Fig. 4 A, B). There was no significant 
difference in VGCC peak current density 
between control (–72.2 ± 8.2 pA/pF, n = 13) and 
R1+R2 KD (–51.3 ± 9.1 pA/pF, n = 13) DRG 
neurons. The effect of Vc1.1 on VGCC current 
amplitude in control and R1+R2 KD neurons 
was examined by bath application of Vc1.1 (100 
nM), followed by the application of baclofen (30 
µM).  
Of 7 neurons that exhibited efficient 
functional knockdown of GABAB receptors, 
VGCC current amplitude was inhibited by 29.5 
± 4.2% in response to bath application of 
baclofen. However, control DRG neurons 
exhibited a baclofen-induced decrease of 45.6 ± 
3.7% (n = 7, P = 0.0136) (Fig. 4A-C). The 
remaining VGCC current was not further 
inhibited by bath application of the selective N-
type VGCC antagonist, ω-conotoxin CVID (300 
nM) (data not shown). Bath application of 100 
nM Vc1.1 to control neurons inhibited the 
VGCC current amplitude by 20.9 ± 3.7% (n = 7) 
(Fig. 4A, D). However, in R1+R2 KD neurons, 
the effect of Vc1.1 on the VGCC current was 
significantly impaired, with the current 
amplitude reduced only by 5.2 ± 4.7% (n = 7, P 
= 0.0223) (Fig. 4B, D and Table 1). Note that in 
all neurons of the R1+R2 KD treatment group in 
which baclofen-mediated inhibition of VGCCs 
was impaired, Vc1.1-induced inhibition of 
VGCC currents decreased in all cases. The 
decrease in the number of functional GABAB 
receptors, caused by siRNA knockdown, 
resulted in a functional disruption of GABAB 
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negative coupling to VGCCs. This confirms that 
Vc1.1, similar to baclofen, acts on N-type 
VGCCs via the GABAB receptor. 
The disruption of VGCC current inhibition by 
GABAB receptor knockdown was more 
pronounced for Vc1.1-mediated N-type VGCC 
inhibition than for baclofen-mediated inhibition. 
In R1+R2 KD neurons, N-type VGCC current 
inhibition by Vc1.1 was 75.1% less than the 
current inhibition by Vc1.1 in control neurons, 
whereas baclofen-mediated inhibition decreased 
by only 35.4% (n = 7) in these cells. In all of the 
13 R1+R2 KD neurons tested with baclofen, the 
current inhibition decreased by 41.4%, compared 
with the 13 corresponding control neurons 
(Table 1). Although the present findings 
substantiate previous reports that baclofen and 
Vc1.1 both act via the GABAB receptor (15,16), 
the greater decrease in Vc1.1-mediated 
inhibition, caused by siRNA-mediated GABAB 
receptor knockdown, suggests that the two 
compounds may act via different downstream 
signaling cascades.  
We also evaluated the activity of α-
conotoxins RgIA and AuIB on the GABAB 
receptor in knockdown and control DRG 
neurons. RgIA (100 nM) reduced peak VGCC 
current amplitude in control neurons by 16.2 ± 
3.0% (n = 4) (Table 1) which is consistent with 
previous studies showing RgIA activity on 
untransfected DRG neurons (14,15). In contrast, 
R1+R2 KD neurons considerably decreased 
RgIA-mediated inhibition, with a reduction of 
current amplitude by 3.0 ± 3.2% (n = 4; P = 
0.0245) (Table 1). AuIB (100 nM), an analgesic 
α-conotoxin active at the α3β4 nAChR (20) and 
GABAB receptor (8), also inhibited VGCC 
current amplitude in control neurons, whereas in 
R1+R2 KD cells, inhibition of the VGCC current 
amplitude significantly decreased (n = 3, data 
not shown). Together, these experiments show 
that the activity of these α-conotoxins on N-type 
VGCCs is dependent on GABAB receptor 
expression.  
To demonstrate that the siRNA knockdown 
of the GABAB receptor was specific, control 
experiments examined the effect of µ-opioid 
receptor agonists on VGCC currents in 
transfected DRG neurons. Activation of µ-opioid 
receptors by agonists, such as Met-enkephalin 
and DAMGO, have been shown to inhibit the N-
type VGCC current via activation of a pertussis-
toxin sensitive G protein-coupled receptor 
(24,25). Similar to these findings, we observed a 
wide variation in the sensitivity of individual 
DRG neurons to DAMGO, with some neurons 
almost non-responding. The different 
sensitivities corresponded to different 
populations of DRGs, because the isolated 
neurons originated from ganglia of all regions 
along the spinal cord. As neurons studied were 
chosen at random, any statistical difference in 
VGCC current inhibition between R1+R2 KD 
and control neurons would suggest an effect of 
the knockdown on µ-opioid receptor signaling. 
However, we did not observe any statistically 
significant difference in the inhibition of VGCC 
currents by 1 µM DAMGO between R1+R2 KD 
neurons (18.9 ± 5.2%, n = 5; P = 0.3083) and 
scrambled, non-targeting siRNA-transfected 
control neurons (12.5 ± 2.8%, n = 5) (Table 1). 
This result confirmed that the impairment of 
VGCC current inhibition by baclofen, Vc1.1, 
RgIA and AuIB in GABAB knockdown neurons 
was a result of decreased GABAB receptor 
expression, rather than nonspecific effects of the 
GABAB receptor-targeting siRNAs.  
Reconstitution of the human GABAB receptor 
signaling pathway in HEK 293 cells – To 
demonstrate that both subunits of the human 
GABAB receptor are needed to inhibit Cav2.2 
channels with α-conotoxin Vc1.1, we 
reconstituted the GABAB receptor signaling 
pathway in HEK 293 cells stably expressing 
Cav2.2 channels (Cav2.2 cells). This was done by 
co-transfecting cDNAs of cloned human GABAB 
receptor subunits (R1 and R2) (Fig. 5).  
In HEK 293 cells with Cav2.2 alone (control), 
peak Ba2+ currents were not affected by α-
conotoxin Vc1.1 (200 nM). However, the 
selective N-type (Cav2.2) VGCC inhibitor, ω-
conotoxin MVIIA (200 nM), almost completely 
inhibited the inward Ba2+ current (Fig. 5A). In 
cells expressing Cav2.2 and co-transfected with 
GABAB R1 and R2 (Cav2.2+R1+R2 cells), 
Vc1.1 and baclofen caused inward Ba2+ current 
inhibition, indicated by the decrease of peak 
current amplitude during the administration of 
these compounds (Fig. 5B, C). Similarly, α-
conotoxin Rg1A (200 nM) inhibited inward Ba2+ 
current only in Cav2.2+R1+R2 cells (data not 
shown). However, the effect of Vc1.1 (200 nM) 
or baclofen (100 μM) was absent in Cav2.2 cells 
transiently transfected with the dopamine 
receptor D2 (data not shown). In Cav2.2+R1+R2 
cells, the inhibition of Cav2.2 channels by Vc1.1 
could be blocked by the selective GABAB 
receptor antagonist CGP55845 (Fig. 5C). In 
Cav2.2+R1+R2 cells, Vc1.1 and baclofen caused 
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40 ± 7% (n = 5) and 65 ± 5% (n = 7) inhibition 
of the depolarization-activated inward Ba2+ 
current amplitude, respectively, whereas in 
Cav2.2, Cav2.2+R1, or Cav2.2+R2 cells, 
inhibition of the Ba2+ current was not observed 
(Fig. 5D). In summary, these data demonstrate 
that functional expression of both R1 and R2 
subunits are needed for the inhibition of Cav2.2 
channels by Vc1.1 in the heterologous HEK 293 
cell expression system. 
 
DISCUSSION 
This study demonstrates that functional 
GABAB receptors are needed to observe the 
analgesic α-conotoxins Vc1.1 and RgIA 
decrease N-type VGCC peak current amplitude. 
While previous pharmacological studies showed 
that Vc1.1 and RgIA can inhibit VGCC currents 
in rodent DRG neurons via activation of the G 
protein-coupled GABAB receptor (8,15,16), 
there were no molecular studies showing the 
need for expression of both GABAB receptor 
subunits.  
We chose a knockdown approach to 
demonstrate dependence of α-conotoxin activity 
on GABAB receptor expression, because RNAi 
is a powerful tool for the investigation of 
molecular signaling cascades and siRNAs have 
already been successfully used for knockdown of 
GABAB receptor subunits (26-28) and other 
target receptors and ion channels in pain 
pathways (29,30). In siRNA knockdown 
experiments, we show that the inhibition of N-
type VGCC currents in rat DRG neurons by α-
conotoxins decreased following a transient 
knockdown of GABAB receptors. The 
effectiveness of the siRNA knockdown was 
underscored by qRT-PCR and 
immunocytochemistry, showing a decrease in 
GABAB receptor mRNA and protein expression, 
respectively.  
Results from the GABAB receptor 
knockdown study were reinforced by a 
complementary approach using HEK 293 cells. 
These cells represent an established expression 
system for various membrane proteins (receptors 
and ion channels) and have been used to study 
signaling of heterologously expressed GABAB 
and other G protein-coupled receptors (14,31). 
By co-transfecting both human GABAB receptor 
subunits into HEK 293 cells stably expressing 
Cav2.2 channels, we were able to reconstitute the 
GABAB receptor signaling pathway. In these 
cells, baclofen and α-conotoxins Vc1.1 and 
RgIA decreased Cav2.2-mediated Ba2+ currents. 
However, cells expressing the Cav2.2 channels 
alone, or only one of the two GABAB receptor 
subunits, were insensitive to baclofen and Vc1.1. 
Thus, we have demonstrated that functional 
GABAB receptors are the pharmacological target 
of α-conotoxins Vc1.1 and RgIA. We have also 
shown that functional GABAB receptor 
expression is needed for the inhibition of Cav2.2 
channels. 
Our electrophysiological findings on GABAB 
receptor knockdown show that in control DRG 
neurons, the effect of Vc1.1 and RgIA on N-type 
VGCC currents was substantially less than that 
of baclofen. Moreover, Vc1.1 and baclofen 
clearly differed in their susceptibility to GABAB 
receptor knockdown. Inhibition of N-type 
VGCC currents in GABAB knockdown DRG 
neurons by Vc1.1 was almost completely 
abolished. In contrast, even though the effect of 
baclofen was significantly impaired, inhibition 
of VGCC current was still observed. These 
observations corroborate previous findings, 
indicating that Vc1.1 and baclofen act on N-type 
VGCCs via different pathways, both involving 
the GABAB receptor (15). N-type VGCCs can be 
inhibited by two distinct G protein-dependent 
inhibitory pathways: voltage-dependent and 
voltage-independent (32). Voltage-dependent 
inhibition is the most common pathway, 
involving Gβγ binding directly to the α-subunit 
of the N-type VGCC (33,34). The inhibition of 
N-type VGCCs in DRG neurons by α-conotoxin 
Vc1.1 is voltage-independent and activates a 
pathway that involves src tyrosine kinase (15). 
The GABAB receptor agonist baclofen and its 
inhibition of VGCC currents is well 
characterized (35-37) and appears to inhibit N-
type VGCC currents predominately via the 
voltage-dependent pathway (32). These results 
suggest that the Vc1.1-mediated, voltage-
independent pathway is more sensitive to 
GABAB receptor knockdown (partial 
knockdown) than the baclofen-mediated, 
voltage-dependent pathway.  
Our findings not only strengthen the 
pharmacological significance of the observed N-
type VGCC inhibition by α-conotoxins, Vc1.1 
and RgIA, but extend them to show that these α-
conotoxins are active at human GABAB 
receptors. In vivo studies have shown that Vc1.1, 
RgIA and AuIB administered intramuscularly in 
rats can potently suppress neuropathic pain 
following partial nerve ligation (6-8). To date, 
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there are at least five α-conotoxins which inhibit 
N-type VGCCs in DRG neurons and the three 
that have been tested in animal pain models are 
analgesic. Further studies of the structure–
activity relationships are likely to identify the 
specific residues that confer potency and 
selectivity for the GABAB receptor, and will 
improve understanding of how α-conotoxins act 
on the GABAB receptor. In future, other α-
conotoxins and analogues activating the GABAB 
receptor may be discovered, making the human 
GABAB receptor a novel target for drugs used to 
treat neuropathic pain.  
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FIGURE LEGENDS 
 
FIGURE 1. GABAB receptor mRNA knockdown by siRNA treatment in rat DRG neurons. 
Transfection of siRNA (100 nM) targeting GABAB receptor subunits GABAB R1 (R1 KD) and 
GABAB R2 (R2 KD) resulted in a knockdown by 67 ± 3% (n = 4) of R1 (A) and a knockdown by 46 ± 
8% (n = 4) for R2 mRNA levels (B), respectively, compared with a negative control in which cells 
were transfected with an equal concentration of a scrambled, non-targeting siRNA. Co-transfection of 
R1- and R2-targeting siRNAs (R1+R2 KD) resulted in knockdown levels similar to single subunit 
knockdowns (66 ± 6%, and 47 ± 13%, respectively; n = 5). The mRNA levels were determined by 
qRT-PCR, calculated by comparative quantitation analysis and normalized to the expression levels of 
water transfected cells (*P < 0.05 and ***P < 0.0001 versus control).  
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FIGURE 2. GABAB receptor immunofluorescence is reduced in GABAB knockdown DRG 
neurons as observed using confocal microscopy. Immunolabeling of DRG neurons and visual 
inspection by confocal microscopy revealed an apparent decrease in fluorescence intensities for 
GABAB R1 and GABAB R2 in neurons transfected with siRNAs to disrupt GABAB R1 and R2 
expression, when compared with scrambled, non-targeting siRNA-transfected DRG neurons. Cells 
were immunostained 3 days after transfection, using antibodies directed against R1 (green) (A), or 
against R2 (green) (B). Immunostaining of βIII-tubulin is shown in red. Representative images are 
shown. Scale bars represent 50 µm. 
 
FIGURE 3. Quantitative evaluation of protein levels in GABAB R1 knockdown DRG neurons by 
high-content imaging analysis revealed significantly reduced GABAB R1 expression. DRG cells 
transfected with siRNAs targeting both GABAB receptor subunits (R1+R2 KD) were compared with 
control cells transfected with scrambled, non-targeting siRNA (control). Quantitative analysis of 
immunofluorescence-labeled R1 proteins in DRG neurons 2–3 days after transfection revealed 
significantly reduced R1 protein expression in knockdown cells (R1+R2 KD). (A) Representative 
sites of the high-content scan of a total of 756 sites per treatment group. DRG neurons showing weak 
green fluorescence, indicating low expression of R1 (white arrows), were counted as neurons with R1 
expression below threshold in the statistical analysis. Scale bars represent 50 µm. (B) Percentage of 
neurons exhibiting R1 immunofluorescence above threshold, which correlates to high R1 expression 
levels. (C) R1 expression levels of neurons with R1 expression above threshold calculated from 
fluorescence intensities. Number of experiments indicated in parentheses (*P < 0.05 and ***P < 
0.0001 versus control). 
 
FIGURE 4. Inhibition of N-type calcium channels in response to baclofen and Vc1.1 is 
attenuated in DRG neurons transfected with siRNAs targeting the GABAB receptor. A and B 
show superimposed traces of depolarization-activated VGCC currents in the absence (control) and the 
presence of Vc1.1 (100 nM) and baclofen (30 µM) in scrambled, non-targeting siRNA (A) and 
GABABR knockdown siRNA (B) transfected rat DRG neurons. (C, D) Bar graph summary of data on 
the reduction of peak VGCC current amplitude in the presence of baclofen (C) and Vc1.1 (D). The 
VGCC inhibition by Vc1.1 observed in R1+R2 KD neurons was significantly lower than the VGCC 
inhibition in control neurons. Number of experiments indicated in parentheses (*P < 0.05 versus 
control). 
 
FIGURE 5. Inhibition of stably expressed Cav2.2 channels in HEK 293 cells transiently co-
transfected with human GABAB receptor subunits (R1 + R2) by α-conotoxin Vc1.1 and 
baclofen. (A-C) Peak Ba2+ current amplitude, elicited by 0.1 Hz step depolarization to −10 mV from a 
holding potential of −80 mV, plotted as a function of time (bottom). Bars indicate bath application of 
various compounds. Representative inward Ba2+ current traces (top insets) are shown at the times 
marked by lowercase letters. Dotted line indicates zero current level. (A) In HEK 293 cells expressing 
Cav2.2 channels alone, depolarization-activated Ba2+ currents are not affected by α-conotoxin Vc1.1 
(200 nM), but are almost completely inhibited by ω-conotoxin MVIIA (200 nM). (B) In 
Cav2.2+R1+R2 cells, bath application of Vc1.1 (200 nM) inhibits inward Ba2+ current amplitude. (C) 
In Cav2.2+R1+R2 cells, the effect of Vc1.1 was reduced by the selective GABAB receptor antagonist 
CGP55845 (1 μM), whereas baclofen (50 μM), applied after the washout of CGP55845, inhibited the 
inward Ba2+ current. (D) Bar graph summary of the inhibition of peak Ba2+ current by Vc1.1 (200 nM) 
and baclofen (50 μM) in the absence of GABAB receptor subunits (Cav2.2 alone; control), or in the 
presence of Cav2.2 channels and R1, R2, or R1+R2. Number of experiments indicated in parentheses 
(*P < 0.0001 versus control). 
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TABLES 
 
TABLE 1. Relative GPCR-mediated decrease in VGCC peak current amplitude in control and 
R1+R2 KD DRG neurons 
 
Compound % Inhibitiona 
(Control) 
% Inhibitiona 
(R1+R2 KD) 
n Pb % siRNA 
Attenuationc 
Vc1.1 20.9 ± 3.7 5.2 ± 4.7 7 0.0223 75.1 
RgIA 16.2 ± 3.0 3.0 ± 3.2 4 0.0245 81.7 
Baclofen 38.8 ± 3.5 20.7 ± 3.8 13 0.0018 41.4 
DAMGO 12.5 ± 2.8 18.9 ± 5.2 5 n.s. – 
 
aInhibition of VGCC peak current amplitude following addition of the compound indicated is 
calculated as 100 – I/I0 x 100 
bP value indicates statistical significance of the difference in VGCC peak current amplitude inhibition 
in R1 + R2 neurons versus control neurons (% inhibition of control versus inhibition of R1 + R2 KD). 
n.s., not significant 
cPercentage of reduction of normalized current amplitude inhibition in knockdown cells compared 
with control cells is calculated as 100 – 100/Inhibition(Control) x Inhibition(R1+R2 KD) 
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Figure 2. 
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Figure 3. 
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Figure 5. 
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